Clinical trials: Esophagogastric Junction
ctDNA, Gastric Cancer
Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma
This is a single-center, prospective, exploratory study evaluating the use of dynamic circulating tumor DNA (ctDNA) monitoring in the postoperative adjuvant treatment setting for patients with stage III or stage IVA gastric or…
- Conditions
- ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment
- Trial name
- NCT07507916
- Testing
- HLX10, SOX Chemotherapy
- Volunteers
- 32 people
- Sponsor
- Fudan University
Gastric, Colorectal Adenocarcinoma
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Objective of this study to evaluate 1-year disease-free survival in patients with dMMR/MSI-H or POLE/POLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after…
- Trial name
- NCT06118658
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- China Medical University, China
Gastric Cancer, Stomach Cancer
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
- Trial name
- NCT00858338
- Testing
- Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in patients with HER2-positive /HER2-low locally advanced or metastatic gastric/ gastroesophageal…
- Trial name
- NCT05141747
- Testing
- MRG002
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Miracogen Inc.
Advanced Gastric Cancer, Gastro-esophageal Junction Cancer
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
- Trial name
- NCT01084330
- Testing
- AUY922, Docetaxel, Irinotecan
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
This is a phase II open-label study to evaluate the efficacy and safety of zanidatamab combined with chemotherapy as neoadjuvant/conversion therapy in patients with HER2-positive (IHC 3+ or IHC 2+) locally advanced or metastatic…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
- Trial name
- NCT07685704
- Testing
- Zanidatamab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhifeng Zhao, PhD
OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific.
- Conditions
- OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Oesophageal Cancer Nos
- Trial name
- AROMA2 (NCT07260734)
- Testing
- Breath Test
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
This phase II trial is studying how well bortezomib with or without irinotecan works in treating patients with gastroesophageal junction or stomach cancer that can not be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00061932
- Testing
- bortezomib, irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Gastric or Esophagogastric Junction Adenocarcinoma
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
This multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy)…
- Trial name
- NCT05180734
- Where
- 71 sites in China
- Volunteers
- 878 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ
Gastric cancer is the third leading cause of death due to cancer worldwide. Although the consensus on the surgical treatment has resulted in the improvement of curative effect during the past decades, controversies remained for…
- Trial name
- RARE (NCT05941481)
- Testing
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene
Gastric Adenocarcinoma
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
This is a prospective, single-arm, investigator-initiated phase II clinical study. The study evaluates the efficacy and safety of retlirafusp alfa (a PD-L1/TGF-βRII bifunctional fusion protein) combined with apatinib (a VEGFR-2…
- Trial name
- RA-A-NP (NCT07610629)
- Testing
- Retlirafusp alfa + Apatinib + Nab-paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Oesophageal Cancer, Gastro-Oesophageal Junction Cancer
A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer
SOlar is a multi-centre phase II clinical trial of single agent olaparib in advanced oesophagogastric cancer.
- Conditions
- Oesophageal Cancer, Gastro-Oesophageal Junction Cancer, Gastric Cancer
- Trial name
- SOLAR (NCT03829345)
- Testing
- Olaparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction
Perioperative Chemo and Pembrolizumab in Gastric Cancer
This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in subjects with gastric or gastroesophageal (GE) junction adenocarcinoma.
- Trial name
- NCT02918162
- Testing
- Pembrolizumab, Standard of care chemotherapy regimen
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Gulam Manji
Gastric Cancer
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
This study will be conducted to understand real-world treatment patterns, participant characteristics (demographic and clinico-pathological characteristics), clinical outcomes and safety of different treatment regimens, and…
- Trial name
- NCT05606094
- Where
- 31 sites in China, Hong Kong and 2 more
- Volunteers
- 450 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
This single-arm, open-label study will evaluate the safety and efficacy of the combination oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy in the adjuvant setting in participants with curatively resected HER2+…
- Trial name
- TOXAG (NCT01748773)
- Testing
- Oxaliplatin, Radiation, Capecitabine
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
This early phase I trial studies the effect of pembrolizumab and lenvatinib in treating patients with gastroesophageal adenocarcinoma that has spread to other places in the body (advanced/metastatic) or cannot be removed by…
- Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT05041153
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to investigate the safety and efficacy of conversion therapy using HFRT combined with ICT in locally advanced or metastatic unresectable GEJA.
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
- Trial name
- NCT07072351
- Testing
- hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor
- Where
- 4 sites in China
- Volunteers
- 88 people
- Sponsor
- West China Hospital
Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
This is a single-arm, open-label, clinical study to evaluate the safety of HER2 tumor vaccine injection alone/in combination with standard of care chemotherapy in patients with HER2/neu overexpressing gastric or gastroesophageal…
- Trial name
- NCT05315830
- Testing
- HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.